脂在心力衰竭中的作用
Rana Hamouche1, Scott A Summers2, William L Holland2
1Nora Eccles Harrison Cardiovascular Research and Training Institute, University of Utah, Salt Lake City, UT 84112, USA.
European heart journal open
|May 5, 2025
概括
在心力衰竭 (HF) 中发生变化的脂质会影响心脏功能. 了解它们在减少喷射分数 (HFrEF) 和保持喷射分数 (HFpEF) 的高压中所扮演的角色可能会导致新的治疗方法.
科学领域:
- 心脏病学 心脏病学
- 生物化学 生物化学
- 细胞的新陈代谢
背景情况:
- 晚期心力衰竭 (HF) 涉及心脏肌肉的代谢转变,从脂肪酸氧化转向糖解.
- 这种代谢变化导致脂质代谢物的积累,例如脂,导致心脏脂毒性和功能障碍.
- HF被分为具有减少喷射分数 (HFrEF) 的HF和具有保留喷射分数 (HFpEF) 的HF,具有明显的细胞差异.
研究的目的:
- 审查脂在HFrEF和HFpEF中的作用.
- 探索螺旋脂代谢如何在不同HF类型中促进心脏功能障碍.
- 为了识别HF的脂信号通路内潜在的治疗点.
主要方法:
- 对现有关于脂和心力衰竭的动物和人类研究的审查.
- 对代谢途径的分析,特别是心肌细胞中的ATP生产转移.
- 检查特定的斯芬戈脂类的作用,如胺和斯芬戈-1-酸盐.
主要成果:
- 脂积累,特别是胺,与心脏功能障碍和疾病进展有关.
- 不同的HF类型 (HFrEF与HFpEF) 可能会表现出不同的脂样和代谢变化.
- 化物中的一种代谢物斯芬戈辛-1-酸盐显示出潜在的心脏保护作用.
结论:
- 脂在HFrEF和HFpEF的病理生理学中起着至关重要的作用.
- 针对异常的脂代谢和信号通路提供了一个有前途的治疗策略HF.
- 需要进一步的研究来将这些发现转化为心力衰竭患者的临床应用.
相关概念视频
01:17Pathophysiology of Heart Failure
1.4K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
1.4K
01:26Heart Failure Drugs: Inotropic Agents
426
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
426
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
321
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
321
01:23Imbalances in Cardiac Output
1.2K
The heart's primary function is to pump blood throughout the body, maintaining a balance between blood sent out (cardiac output) and blood returning (venous return). If this balance is disrupted, it can result in congestive heart failure (CHF), a severe condition where the heart becomes an inefficient pump, leading to inadequate blood circulation.
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
CHF can occur due to the failure of either side of the heart. Left-side failure leads to pulmonary congestion—the right side continues to...
1.2K
01:22Heart Failure Drugs: Diuretics
295
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
295
01:22Heart Failure Drugs: β-Blockers
278
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
278